More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/6/15 *Est.)
- Conference (6/2/2015)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 39.41M
Marketable securities 50.62M
Proceeds from sale of RXi, received January 6, 2011
Receivable 3.49M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 75.54K
Prepaid expenses and other current assets 2.08M
Total current assets 95.68M
Equipment and furnishings, net 824.49K
Goodwill 183.78K
Other assets 119.5K
Total assets 96.81M
Current liabilities:
Accounts payable 5.42M
Accrued expenses and other current liabilities 8.57M
Warrant liabilities 4.62M
Total current liabilities 18.61M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 55.92K
Additional paid-in capital 373.78M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) -2.58M
Accumulated deficit -293.07M
Total stockholders' equity 78.19M
Total liabilities and stockholders' equity 96.81M